Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Medical Tech. Receives Approval for Cancer Drug Test

publication date: Nov 10, 2010
China Medical Technologies was granted approval by the SFDA for its real-time PCR-based Epidermal Growth Factor Receptor Assay. The EGFR PCR Assay is used to detect the 28 most common mutations in the EGFR gene in patients with non-small cell lung cancer, predicting the efficacy of targeted cancer drugs. EGFR abnormalities have been found in approximately 85% of NSCLC patients who responded to Iressa or Tarceva. More details....

Stock Symbol: (NSDQ: CMED)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital